In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Synthetic Biologics (SYN - Research Report), with a price target of $4.00. Maxim Group Sticks to Its Buy Rating for Synthetic Biologics (SYN)
(NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fundació Sant Joan de Déu that further support evaluation of VCN-01, an oncolytic adenovirus expressin 30, 2022 (GLOBE NEWSWIRE) - Synthetic Biologics, Inc. Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastomaROCKVILLE, Md., Sept. Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma The new name, logo and branding elements were introduced to better reflect Theriva’s position as a clinical-stage pharmaceutical company developing a novel oncolytic a (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc.
12, 2022 (GLOBE NEWSWIRE) - Theriva Biologics, Inc. Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. Synthetic Biologics Rebrands as Theriva Biologics Below are the latest news stories about SYNTHETIC BIOLOGICS INC that investors may wish to consider to help them evaluate SYN as an investment opportunity.
0 kommentar(er)
